Gilead Q2 Shows Core HIV and New Drug Strength, Bolstering Growth Narrative

What happened

Gilead's Q2 2026 results reveal robust performance from cornerstone HIV drug Biktarvy, with sales reaching approximately $3.77 billion, a 6.9% YoY and 12.2% QoQ increase. This extends the HIV franchise's momentum and underscores the durability of Gilead's cash-generating core, which remains protected by patent settlements until 2036. Meanwhile, the recently launched Livdelzi (PPARδ agonist) generated $167 million in revenue, surging 114% YoY and offering an early sign of pipeline diversification. The strong quarter supports the narrative that the market may be underestimating Gilead's growth, as highlighted by Seeking Alpha's rating upgrade. However, the positive sales data does not address the overhang from ~$11.5B in Q2 acquired IPR&D charges and the critical need for Yeztugo's utilization ramp and the August 27 FDA decision for BIC/LEN.

Implication

The strong Q2 print from Biktarvy and Livdelzi reduces near-term revenue risk and may attract value-conscious investors to the HIV cash-flow durability story. However, the heavy IPR&D charges expected in Q2 2026 will still drive a GAAP loss, potentially capping share price gains until clean earnings emerge. The growth of Livdelzi adds a small but promising non-HIV leg, though its impact on total revenue remains modest. The investment case continues to hinge on Yeztugo converting payer coverage into sustained demand and the successful approval of BIC/LEN, with oncology catalysts (anito-cel PDUFA in December) providing optionality. Maintain a cautious but constructive stance, using price weakness from charge-related headlines as an opportunity to accumulate ahead of catalysts.

Thesis delta

The Q2 data strengthens the base-case assumption of durable HIV cash flows and introduces an additional growth driver in Livdelzi, but does not alter the central investment thesis. The thesis remains contingent on Yeztugo's commercial execution and regulatory milestones, with the ~$11.5B IPR&D charge still an overhang. The incremental data modestly increases conviction that the core business can fund the pipeline transition.